EU clopidogrel recall suggested after India plant fails GMP inspection
This article was originally published in The Gold Sheet
The European Medicines Agency's Committee for Medicinal Products for Human Use on March 25 recommended a recall to the pharmacy level of all clopidogrel products made for the European market with active pharmaceutical ingredient that was produced by Glochem Industries at its plant in Visakhapatnam, India. Inspectors from Germany acting for EMA determined in an inspection that the plant was not compliant with EU GMPs. Swiss-based Acino Pharma markets clopidogrel, generic for Plavix, with API made from the site, as do its marketing partners A1 Pharma, Hexal, Sandoz and ratiopharm
You may also be interested in...
CHF Solutions adds “CEO” to its president’s job title; Agilent VP of business development promoted to senior VP; Zimmer hires chief transformation officer; and more.
Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.
EU Business Round-Up: Galenica Boosted By Deals, Alliance's Sales Rise, And Beiersdorf Relaunches Wound Care
Latest EU business news: Galenica posts sales up in 2020 thanks to deals; Alliance Pharma's Consumer sales edge up despite COVID-19; and Beiersdorf is relaunching its wound care range with sustainability in mind.